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Objectives: Rapid human immunodeficiency virus (HIV) antibody tests, routinely used for diagnosis in adults and older children 
in resource-limited settings (RLS), do not detect early HIV infections prior to seroconversion or when antibody levels are still low. 
Nucleic acid amplification to detect HIV-1 RNA is the most sensitive method for acute HIV infection diagnosis, but is costly. We 
therefore investigated HIV- 1 RNA testing of pooled dried blood spots (DBS) to diagnose acute HIV infection.
Design: Laboratory-based investigation.
Methods: DBS were collected from HIV-1 Voluntary Counselling and Testing (HVCT) clients who tested negative on the Advanced 
QualityTM HIV antibody rapid test. DBS samples from five participants were pooled and tested on the COBAS AmpliPrep/COBAS 
TaqMan HIV-1 (CAP/CTM) Test v2. Individual DBS were tested when pools tested positive (> 200 RNA copies/ml). Acute infection 
was confirmed by HIV viral load testing, two fourth-generation HIV serological assays, and Geenius™ HIV 1/2 Assay for antibody 
band identification.
Results: Of 482 participants who were tested, one (0.2%) had acute HIV infection: Fourth generation serology was low-level 
positive, the plasma HIV viral load was 15 929 HIV-1 RNA copies/ml, gp160 and gp41 antibody bands were positive and the p31 
band was negative, indicating a Fiebig Stage 5 infection.
Conclusions: Pooled DBS HIV-1 RNA testing is efficient compared to individual testing for acute HIV infection diagnosis. Early 
identification of participants with acute HIV infection facilitates immediate initiation of antiretroviral therapy to improve immune 
recovery and prevent transmission to others.
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Background
There were an estimated 380  000 new HIV infections in South 
Africa in 2015,1 highlighting the urgent need to improve 
prevention efforts. In the HIV Prevention Trials Network (HPTN) 
052 study, antiretroviral therapy (ART) reduced transmission by 
96% in serodiscordant couples.2 At the community level, 
increased ART coverage is associated with a lower incidence, 
likely by reducing transmissibility between partners.3 
Epidemiological models support therapy as prevention and early 
ART in patients with CD4 counts above 500 cells/μl provides 
individual benefit.4–6 Therefore, the latest World Health 
Organisation (WHO) and South African guidelines recommend 
initiation of ART as early as feasible. However, many early HIV 
infections remain undetected. Acute and early HIV infection is 
defined as the period from exposure until approximately 
100  days,7 when individuals are highly infectious due to high 
viral loads in blood and genital secretions.8 International studies 
have shown that as many as 20-50% of HIV-1 transmission events 
could be from sexual exposure to an acutely infected individual.9,10 
HIV voluntary counselling and testing (HVCT) relying on rapid 
antibody tests may miss patients with acute or early HIV infection 
before antibodies are detectable.7,11
Nucleic acid tests (NAT) for HIV-1 RNA and/or DNA are the most 
sensitive for diagnosing acute HIV infection.7 In South Africa, due 
to high costs, NAT to diagnose acute HIV infection is only used in 
high risk settings.12,13 As few rapid test-negative individuals are 
expected to have acute HIV infection, pooled HIV-1 RNA testing 
on plasma increases testing efficiency. This approach has been 
established but still requires phlebotomy, which makes it 
unsuitable for many typical HVCT settings.14–16
Many studies have demonstrated that dried blood spots (DBS) 
are useful for infant HIV diagnosis and monitoring plasma HIV 
viral loads with an excellent analytical performance.17–19 However, 
no data is available for a DBS testing pooling strategy to diagnose 
acute and early adult HIV infections. In this study, we investigated 
whether pooled dried blood spot (DBS) testing might be a 
feasible method to identify acute HIV infection in a moderate risk 
HVCT setting.
Methods
The study was approved by the Stellenbosch University Health 
Research Ethics Committee (N15/09/080). To establish the lower 
limit of detection of the DBS testing approach, we serially diluted 
HIV positive plasma samples with known HIV RNA loads and 
artificially reconstituted whole blood by mixing with the cellular 
fraction of whole blood samples (50%) from HIV-negative donors. 
Fifty microlitres of each constituted specimen was pipetted onto 
Whatman 903 sample collection cards (GE Health Sciences, 
Buckinghamshire, England) and allowed to dry overnight at 
room temperature. One known positive HIV RNA DBS sample per 
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dilution was added to four known HIV negative DBS and tested 
on the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 (CAP/
CTM) (Roche Molecular Diagnostics, Pleasanton, CA) in 8-10 
replicates per dilution. The limit of detection was estimated by 
probit regression using the R statistical software package, version 
3.3.1.20
We collected and tested samples from participants who provided 
informed consent from March 2016 to August 2016. Our study 
population included participants who self-referred for 
community-based HIV testing at either a stand-alone centre or at 
a mobile service in one of five peri-urban communities around 
Cape Town. Mobile services were typically set up at transport 
hubs, along major thoroughfares and in high schools. This 
community-based HIV testing service was part of a routine 
service delivery. Participants who tested negative on the 
Advanced QualityTM HIV antibody screening assay (Intec Products 
Inc., Haicang, Xiamen, China) had five DBS of 50 μl each collected 
through finger prick on Whatman 903 cards for further testing. 
The DBS samples were allowed to dry overnight and then kept 
frozen at –20  °C until testing. We excluded DBS samples that 
contained visibly less than 50 μl per DBS.
The same DBS testing algorithm was followed throughout 
(Figure 1). DBS from five sequential participants constituted a 
minipool. The five punched-out DBS were placed in a 1.5  ml 
Eppendorf tube together with 1.4 ml of pre-extraction reagent 
(SPEX) buffer and then placed on a shaker at 56-57  °C for 30 
minutes. Thereafter the sample was centrifuged at 13 000 g for 
2 min and 1.1 ml of supernatant was removed and placed in a 
clean 1.5 ml Eppendorf tube to be used for further testing.
The pooled sample was tested for HIV-1 RNA on the CAP/CTM 
system. As plasma volumes in DBS were variable and our purpose 
was diagnosis, raw assay values rather than extrapolated plasma 
RNA loads were reported. Pools testing positive were 
deconvoluted by testing the five constituent samples separately. 
For this, individual DBS samples were placed in 1.5 ml Eppendorf 
tubes and 1.1 ml of SPEX buffer was added. Pre-extraction and 
testing were the same as for the sample pools. At the study 
outset, we found a case with detectable pool and detectable 
individual viral load  <  200 copies/ml, who was recalled for a 
confirmatory sample that tested RNA and antibody negative. We 
also found 4 detectable pools < 200 copies/ml without detectable 
individual samples. Therefore, considering the impact of a false 
provisional positive diagnosis using an approach not yet 
validated for diagnosis, we subsequently regarded > 200 copies/
ml as a threshold for deconvolution of pools and confirmatory 
testing of individual DBS positive samples.
To confirm acute HIV infection and perform Fiebig staging, an 
individual testing positive on DBS was asked to visit a health care 
site for phlebotomy to collect a confirmatory sample as soon as 
possible. The HIV viral load in the confirmatory sample was 
determined by the CAP/CTM. In addition, it was tested on two 
sensitive fourth generation HIV serology platforms: The Abbott 
Architect i200SR immunoassay analyser (Abbott Laboratories, 
Abbott Park, Illinois, USA) and the Mini-Vidas HIV Duo 
immunoassay (Biomerieux Vitek Inc., Missouri, USA) which is 
designed to specifically and sensitively detect the p24 antigen in 
the absence of HIV antibody. In participants positive for 
antibodies, the HIV antigen reactivity pattern was confirmed 
with the GeeniusTM HIV 1/2 Assay (BioRad, Marnes-la-Coquette, 
France).
Results
The pooled DBS HIV-1 RNA testing lower limit of detection (95% 
hit rate) was an individual sample plasma HIV-1 RNA load of 
2 629 (95% confidence interval: 1 258 – 7 236) copies/ml.
Two samples were excluded from the study for the following 
reasons: one mistaken enrolment of a known antibody positive 
individual with chronic HIV infection; and, one individual without 
a second DBS, not allowing deconvolution. Of the 482 samples 
included, one showed acute HIV infection (0.2%). For this patient, 
the HIV viral load of the minipool was 29 649 copies/ml and the 
deconvoluted individual DBS HIV viral load 15  929 copies/ml. 
There was a delay of 14  days from the original DBS sample to 
testing a confirmatory sample. At this stage, the laboratory 
serology was already a low positive for HIV antibody and the 
plasma HIV-1 RNA load was 58  092 copies/ml. The GeeniusTM 
assay showed gp160 and gp41 bands, but p31 was negative. This 
patient was classified with acute HIV infection, Fiebig Stage 5, 
but declined immediate ART.
Discussion
Diagnosing and treating HIV infection as early as possible has 
individual as well as community benefit. It reduces the risk of 
HIV-associated disease and limits transmission.4,5,21,22 Patients 
treated during acute infection are also ideal candidates for 
curative interventions as early therapy prevents immune damage 
and limits seeding of reservoirs.23,24
According to the 2012 Human Science Research Council South 
African National HIV Prevalence, Incidence and Behaviour Survey, 
the overall HIV incidence in 2 – 49-year-old individuals was 1.07%. 
However, as the epidemic is generalised, it is difficult to define risk 
groups, apart from a higher incidence among young black female 
survey participants.25 Moreover, as symptoms of acute HIV 
infection are nonspecific, it is challenging to identify those cases. 
One approach is to perform two parallel rapid tests and, when 
discordant, test individuals for acute infection.26 Another is to use 
epidemiologic and clinical scoring algorithms to identify which 
patients with negative rapid tests are more likely to have acute 
HIV, warranting point-of-care (PoC) HIV NAT testing.7 However, 
such individual PoC NAT testing remains costly.
Figure 1: Algorithm for pooled DBS HIV RNA testing.
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When the frequency of samples with acute HIV infection is low, 
pooled testing would increase efficiency. In settings without 
access to phlebotomy, pooled DBS testing offers a practical 
alternative to pooled plasma testing. However, in contrast to 
plasma, the number of samples that can be pooled with DBS 
testing is limited due to PCR inhibition by haemoglobin or other 
impurities.
There is currently no ideal acute HIV diagnostic testing strategy 
available in resource limited settings. Pooled HIV-1 RNA testing is 
a cost-effective way to utilise HIV-1 RNA testing in trying to 
diagnose acute HIV. Furthermore, a pooled DBS HIV RNA strategy 
foregoes the need for phlebotomy, which will make it easier to 
collect specimens in resource limited settings. Fourth generation 
HIV laboratory based tests are more sensitive than third 
generation rapid tests, but have other problems such as 
increased turnaround time (resulting in possible delays in 
treatment and loss to follow up) and particular automated assays 
may be prone to sample contamination.28 Most fourth generation 
HIV serology platforms are also not validated for testing with 
DBS, but some studies have shown promise.31 Given that the DBS 
technique is currently the only means of sample transport over 
long distances and without the need for cold storage, it will be 
important for manufacturers of laboratory-based tests to validate 
their platforms for use with DBS.29 There is also a need for scalable 
molecular PoC tests and as nucleic acid testing technology 
becomes more compact and affordable, this may be possible in 
the foreseeable future.29
Our study had several limitations. As participants were from 
community-based HIV testing sites, where clinical information 
was not collected, we could not identify individual infection 
risks. Deconvolution of positive pools through individual re-
testing causes delay of a few days, which would likely result in 
Fiebig stage progression by time of follow-up. We were also 
operating in a setting with a high treatment coverage, which 
likely lowered incidence and contributed to finding only one 
true case of acute infection. In such a setting the use of nucleic 
acid testing, even when testing pooled samples, is costly (a 
single HIV viral load test is approximately US$ 25). We also found 
that low positive pools (< 200 copies/ml) were not predictive of 
true infections. The Advanced QualityTM HIV antibody screening 
assay sensitivity is 98.8% (93.2  – 100.0%).27 The most common 
causes for false negativites are early HIV infection and advanced 
HIV infection. In our study, we did not find any chronic HIV 
infections that were missed with initial rapid HIV testing. This is in 
contrast to the previously published study by Bassett et al30 that 
found 2% of patients with chronic HIV infection. This might be 
explained by the difference in the size of the patient cohorts, the 
geographical differences in HIV prevalence and the fact that we 
did not include discordant HIV results in our study.
As far as we know, this is the first report of using pooled DBS 
testing to diagnose acute HIV infection in adults. Our investigation 
showed that pooled DBS testing could be used to identify acute 
HIV infection in rapid test negative individuals at a lower cost 
than individual testing. DBS collection was also feasible at sites 
that perform finger prick for HIV rapid testing. Due to the high 
disease burden, we found it challenging to prioritise diagnosing 
acute HIV infection, both at clinical and laboratory level. The 
study team has been involved in cases, outside this study, where 
treatment of acute HIV infection was delayed, curbing the benefit 
that very early therapy could achieve. Considering the 
accumulating evidence of the benefit of immediate therapy, 
identifying HIV infection could be prioritised as a medical 
emergency. Increased health care worker awareness, with 
improved affordable and feasible diagnostic modalities, is 
needed to initiate immediate ART. Further, larger scale research 
projects evaluating the use of pooled DBS and similar strategies 
are urgently needed to inform future best practice.
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